|
|
 |
|
Viewing report
|
|
|
|
The 111th U.S. Congress Tackles Healthcare Reform and the Pharmaceutical Industry
Decision Resources, Inc., Sep 2009, Pages: 35
In this report, we feature a commentary by Alex M. Brill, CEO of Matrix Global Advisors and a research fellow at the American Enterprise Institute, who testifi ed before the U.S. House Judiciary Committee’s Subcommittee on Courts and Competition on July 14, 2009, regarding data exclusivity for biosimilars. We also provide insights from an interviewed health policy lobbyist who is active in government affairs in Washington, D.C. He spoke on background concerning recent negotiations on healthcare reform, authorized generics, and reverse payment deals. Kevin E. Noonan, J.D., Ph.D., a partner at McDonnell Boehnen Hulbert & Berghoff, gives his insights on patent reform and healthcare reform.
Customers who bought this item also bought
U.S. Healthcare Reform: Impact on the Pharmaceutical Industry
Biosimilars: Beyond the first product wave
The Impact of US Healthcare Reform on Pharma
Biosimilars: A viable market - but when?
Obama's Healthcare Reform Bill and its Impact on the U.S. Healthcare Market
The New Era of Healthcare Reform - Supporting Revenue Growth through Understanding and Adaptation
US Healthcare Reform: Impact and Implications for the Pharmaceutical and Biotech Industries
Hospital Injectable Drugs: Future Prospects for Generics & Biosimilars
Top 10 Healthcare Trends in 2011
Global Biosimilar Market 2010-2014
|
|
|
|
